相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Joining the dots for better liver cancer treatment
Lo-Kong Chan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
Stephen Lam Chan et al.
LIVER CANCER (2020)
Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
Chun Jye Lim et al.
GUT (2019)
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
Ying Fan et al.
BMC CANCER (2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice
Haibang Hao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory C. Fanning et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
HBV-Induced Immune Imbalance in the Development of HCC
Yongyan Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
STAT3, a Master Regulator of Anti-Tumor Immune Response
Cedric Rebe et al.
CANCERS (2019)
Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
Juliane Lokau et al.
CANCERS (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
Gi-Ae Kim et al.
GUT (2018)
Activation of PPAR. mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme
Yongji Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
Chong Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Flavonoids as Th1/Th2 cytokines immunomodulators: A systematic review of studies on animal models
Gopalsamy Rajiv Gandhi et al.
PHYTOMEDICINE (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia
Ke Zhang et al.
MEDIATORS OF INFLAMMATION (2018)
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Le-Xing Yu et al.
NPJ PRECISION ONCOLOGY (2018)
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Rohit Loomba et al.
GASTROENTEROLOGY (2017)
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
Richard Jackson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks
Patrick T. F. Kennedy et al.
VIRUSES-BASEL (2017)
Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy
Hidemitsu Kitamura et al.
CANCER SCIENCE (2017)
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection
Bei-li Wang et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review
Soheil Tavakolpour et al.
HEPATITIS MONTHLY (2016)
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013
Jeffrey D. Stanaway et al.
LANCET (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Screening and diagnosis of HBV in low-income and middle-income countries
Jean-Pierre Allain et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation
Chao Zhang et al.
ONCOTARGET (2016)
Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
Ming-Ying Lu et al.
SCIENTIFIC REPORTS (2016)
Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection
Zhong Fang et al.
JOURNAL OF IMMUNOLOGY (2015)
Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet et al.
Nature Reviews Clinical Oncology (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
Hong Zhao et al.
ONCOTARGET (2015)
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
Ibrahim Jantan et al.
FRONTIERS IN PLANT SCIENCE (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
Tadaaki Arizumi et al.
DIGESTIVE DISEASES (2014)
Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model
Horng-Tay Tzeng et al.
PLOS ONE (2014)
Cytokine patterns in patients with cancer: a systematic review
Bodo E. Lippitz
LANCET ONCOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Joanna S. Brooke
CLINICAL MICROBIOLOGY REVIEWS (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
Ann-Lii Cheng et al.
EUROPEAN JOURNAL OF CANCER (2012)
Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions
Junmin Zhou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma
Fang-Ming Gu et al.
MOLECULAR CANCER (2011)
Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3/AKT Signalings
Jian Feng Zhu et al.
PLOS ONE (2011)
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
Eek Joong Park et al.
CELL (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Indispensable role for TNF-α and IFN-γ at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen
A Ohta et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
